Key Inclusion Criteria:
- Are at least 18 years old (or old enough to legally make their own treatment
decisions, according to local laws).
- Have advanced NSCLC or metastatic NSCLC (NSCLC that started in the lungs and then
spread to other parts of the body) with the KRAS G12C mutation.
- Have had previous treatment with 1) chemotherapy that included a drug called
cisplatin or a drug called carboplatin and 2) a type of drug called an immune
checkpoint inhibitor.
- Have recovered from their prior treatment and blood tests are within a safe range.
Key Exclusion Criteria:
- Have had previous treatment with a drug that targets KRAS G12C.
- Have cancer that can potentially be removed with surgery.
- Patients with brain lesions are not eligible if 1) any untreated brain lesions are >
2.0 cm in size 2) any brainstem lesions are present 3) ongoing steroid dosing >10 mg
daily prednisone (or equivalent) and 4) poorly controlled (> 1/week) generalized or
complex partial seizures or neurologic progression/instability due to brain lesions.
- Have certain medical conditions or need to take certain medications that, in the
opinion of a trial doctor, could make it unsafe for them to participate or difficult
to complete the trial assessments, or are pregnant.
